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Background: Small proline rich protein (SPRR) 2A is one of 14 SPRR genes that encodes for a skin cross-linking
protein, which confers structural integrity to the cornified keratinocyte cell envelope. New evidence, however,
shows that SPRR2A is also a critical stress and wound repair modulator: it enables a variety of barrier epithelia to
transiently acquire mesenchymal characteristics (EMT) and simultaneously quench reactive oxygen species during
wound repair responses. p53 is also widely recognized as the node in cellular stress responses that inhibits EMT and
triggers cell-cycle arrest, apoptosis, and cellular senescence. Since some p53-directed processes would seem to
impede wound repair of barrier epithelia, we hypothesized that SPRR2A up regulation might counteract these
effects and enable/promote wound repair under stressful environmental conditions.
Results: Using a well characterized cholangiocarcinoma cell line we show that levels of SPRR2A expression, similar
to that seen during stressful biliary wound repair responses, disrupts acetylation and subsequent p53 transcriptional
activity. p53 deacetylation is accomplished via two distinct, but possibly related, mechanisms: 1) a reduction of
p300 acetylation, thereby interfering with p300-p53 binding and subsequent p300 acetylation of K382 in p53; and
2) an increase in histone deacetylase 1 (HDAC1) mRNA and protein expression. The p300 CH3 domain is essential
for both the autoacetylation of p300 and transference of the acetyl group to p53 and HDAC1 is a component of
several non-p300 complexes that enhance p53 deacetylation, ubiquitination, and proteosomal degradation. HDAC1
can also bind the p300-CH3 domain, regulating p300 acetylation and interfering with p300 mediated p53
acetylation. The importance of this pathway is illustrated by showing complete restoration of p53 acetylation and
partial restoration of p300 acetylation by treating SPRR2A expressing cells with HDAC1 siRNA.
Conclusion: Up-regulation of SPRR2A, similar to that seen during barrier epithelia wound repair responses reduces
p53 acetylation by interfering with p300-p53 interactions and by increasing HDAC1 expression. SPRR2A, therefore,
functions as a suppressor of p53-dependent transcriptional activity, which otherwise might impede cellular
processes needed for epithelial wound repair responses such as EMT.Background
p53 is a nodal convergence point of integrated intra-
cellular signaling networks that mediate cellular responses
to stress (e.g. oxidative stress or DNA damage). It regu-
lates expression of many stress-related target genes and
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their promoter regions [1]. p53 is tightly regulated, how-
ever, as a “cellular gatekeeper” [2] and the three-step acti-
vation process of p53 is complex: stabilization, DNA
binding, and transcriptional activation [3]. As many as 50
individual posttranslational modifications contribute to or
influence the ability of p53 to function as a sequence-
specific transcription factor during normal homeostasis
and stress-induced responses [4,5].
p53 activation is also modulated by transcriptional co-
activators (e.g. p300 [6]) and inhibited by a variety oftral Ltd. This is an Open Access article distributed under the terms of the
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nates p53 targeting it for proteasome-mediated degrad-
ation. Thus, p53 and MDM2 form a negative feedback
regulatory loop. MDM2-mediated p53 destruction is
synergistic with histone deacetylase 1 (HDAC1): these
molecules often complex together, coupling p53 deacety-
lation and ubiquitination [7].
p53 is also subject to, and exerts, cytoplasmic influ-
ences [8]. p53 phosphorylation by kinases (e.g. ATM/
ATR/DNAPK), and Chk1/Chk2 is regarded as the first
crucial step in p53 stabilization [3]. Post-translational
p53 acetylation helps regulate protein concentrations
and transcriptional activity [9]. Cellular stress (e.g.
H2O2) and over expression of p300/CBP [6] causes
K382-p53 acetylation and p53 protein accumulation [6].
The latter also results in increased sequence specific
p53-DNA binding [10]. Other p53 lysine modifications
such as methylation, ubiquitination, sumoylation, and
neddylation also have the potential to alter p53’s tran-
scriptional activity [4,5].
Typically, p53 enhanced transcriptional activity increases
p21 expression during cellular stress, which in turn, blocks
cell cycle progression and inhibits proliferation. p53 activa-
tion can also block epithelial-to-mesenchymal transition
(EMT) via upregulation of miR-200 and miR-192 family
members that repress ZEB1/2 expression [11], which are
key mediators of EMT. Paradoxically, these p53-directed
stress responses, p21 upregulation and EMT blockage, are
at odds with the two main processes needed in the epithe-
lia for wound repair: proliferation and migration [12].
Small proline rich protein (SPRR) 2A, one of 14 SPRR
genes coded in the region of the epidermal differenti-
ation complex [13], is coordinately expressed with other
genes in the complex. In the normal skin it functions
primarily as a keratinocyte cross-linking protein that
confers structural integrity to the cornified cell envelope
[14]. Exciting new evidence, however, shows non-
coordinate, independent up-regulation of SPRR proteins
occurs almost universally in a variety of pathophysio-
logical conditions involving stress and wound repair in
the barrier epithelia ([15]). Remaining viable epithelial
cells at the edges of wounds transiently undergo
epithelial-mesenchymal transition (EMT) [15,16], a
process essential for the restitution/migration phase of
epithelial wound healing [12].
Previous data from our group showed that forced ex-
pression of SPRR2A in the cholangiocarcinoma cell line
SG231, at levels similar to those seen during wound re-
pair responses, induced EMT and significantly reduced
cell death under H2O2- and glycochenodeoxycholate-
induced cell injury [15]. Parallel observations were made
in keratinocytes [17]. Therefore, beyond its role in skin
cornification, SPRR proteins have a widespread role in
tissue remodeling and function as global links betweenROS detoxification and cell migration during wound
healing [18]. These observations prompted us to test the
hypothesis that stress induced non-coordinate upregula-
tion of SPRR2A in barrier epithelia counteracts the tran-
scriptional activity of p53, thereby enabling cellular
adaptations needed for normal wound repair under
stressful circumstances.
Results and discussion
SPRR2A blocks acetylation of K382-p53
We first determined whether SPRR2A protein expres-
sion in HuCCT-1 cells altered the distribution of Flag-
tagged p53 transfected protein, which it did not. p53 and
SPRR2A proteins were detected in the nucleus and
cytoplasm (Figure 1A), but SPRR2A did not change the
distribution of p53. In contrast, p300 and its cysteine/
histidine-rich (CH) region 3 deletion construct distribu-
ted primarily to the nucleus, but low-level cytoplasmic
localization was also seen (Figure 1B). Cytoplasmic
p300 can ubiquinate p53 and target it for destruction
thereby preventing cytoplasmic p53 accumulation [19].
The intra-cellular distribution of SPRR2A was con-
firmed by expression of a Ds-Red-SPRR2A construct
that showed both nuclear and cytoplasmic protein ex-
pression in HuCCT-1 cells (Figure 1C).
Simultaneous over expression of p53 and p300 signifi-
cantly increased the level of Ac-K382-p53, indicating
that in HuCCT-1 cells, p53 acetylation involves p300
(Figure 1D). Co-transfection of HuCCT-1 with combina-
tions of SPRR2A, p300, and p53 vectors showed the fol-
lowing: 1) In the presence of p300 over expression,
SPRR2A caused a decrease in Ac-K382-p53, both with
and without p53 transfection. 2) SPRR2A transfection
decreased p53 acetylation in the absence of p300 over
expression, suggesting that SPRR2A also influences p53
acetylation/stabilization through other non-p300 related
mechanisms (Figure 1D).
To verify that the SPRR2A reduction in Ac-K382-p53
was not a consequence of p53 and/or p300 over expres-
sion, we used a cell line stably transfected with SPRR2A
alone to determine the effects on endogenous p53. The
SPRR2A clone showed a marked reduction in endogen-
ous Ac-K382-p53 when compared to its vector control
(Figure 1D; lower panel, left). HuCCT-1 cells harbor a
point mutation (H175) in p53, which reduces (but does
not eliminate) binding to the p21 promoter (http://p53.
free.fr/Database/Cancer_cell_lines/p53_cell_lines.html).
Therefore, SPRR2A is capable of decreasing acetylation
of both endogenous (mutant) p53 and transfected (wt)
p53 (Figure 1D). To verify that the reduced acetylation
seen with transfected (wt) p53 was not influenced by the
presence of mutant p53 in HuCCT-1 cells, we examined
the effect of SPRR2A over-expression in a cell line with
(wt) p53. Like HuCCT-1 cells, the human hepatoma cell
Figure 1 (See legend on next page.)
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Figure 1 SPRR2A blocks p300 induced acetylation of K382-p53. (A)Western blotting of nuclear and cytoplasmic protein obtained from
HuCCT-1 cells 48 hours post-transfection with V5-SPRR2A, and FLAG-p53 plasmids. SPRR2A and p53 were detected in both the cytoplasm and
nucleus. SPRR2A expression did not change the distribution of p53. Halo-EGFP vector was used to adjust vector amounts. Lamin A/C and Tubulin
were used to verify nuclear and cytosolic separation, respectively. (B) Western blot analysis of the distribution of acetyltransferases p300 and PCAF
protein 48 hours after transfection with the indicated vectors. P300 and its cysteine/histidine rich region 3 (ΔCH3) deletion construct distribute
primarily to the nucleus, with some protein detected in the cytoplasm. PCAF was only detected in the nucleus. Lamin A/C and tubulin were used
to verify separation of nuclear and cytoplasmic fractions. (C) HuCCT-1 cells transfected with a DsRed-SPRR2A plasmid and SPRR2A protein
visualized via Axiovision, an advanced, automated imaging system (Carl Zeiss, Gottingen, Germany). Axiovision software enables Z-stack capture
(10 stack levels/0.35 micron spacing per level). In the vertical cut surface, the cytoplasm is positive for DsRed-SPRR2A expression. The horizontal
cut surface shows DsRed-SPRR2A co-localized with DAPI staining in the nucleus. (D) Upper panel: Western blotting of Ac-K382-p53 in cells
transfected with indicated vectors shows that SPRR2A reduces Ac-K382-p53, both with and without p300 over-expression. Lower panel, left: A
SPRR2A stable transfectant also shows deacetylation of p53 without p53 or p300 over-expression. Lower panel, right: EP300 siRNA further reduced
Ac-K382-p53 levels in the SPRR2A stable transfectant, suggesting acetylation of p53 occurs through both p300 and non-p300 mediated pathways.
(E) Immunoprecipitation of p300 shows that the presence of SPRR2A reduces p300/p53 binding.
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Figure S1A) and HepG2 endogenous p53 is wild type
[20]. Transient transfection of SPRR2A in HepG2 cells
resulted in a marked reduction of K-382-p53 acetyl-
ation and a corresponding reduction in p21 mRNA
(Additional file 1: Figure S1B-C), confirming a role
for SPRR2A in the acetylation and transactivation of p53.
To determine if the SPRR2A-induced p53 deacetylation
was p300 dependent, we knocked down endogenous p300
expression with siRNA (Figure 1D; lower panel, right). In
both the vector control and SPRR2A clone, removal of
p300 resulted in an increase in total p53, as previously
reported [21] and is attributed to the role of p300 in the
removal of p53 through ubiquitination and proteasomal
targeting [19,22]. In the vector control, loss of p300 causes
a slight increase in Ac-K382-p53, but the ratio of Ac-
K382-p53/total p53 is maintained through compensatory
p300 independent mechanisms (Figure 1D: lower panel
right). If SPRR2A interferes with p53 acetylation solely
through p300, knocking out p300 should restore Ac-
K382-p53 levels to those seen in the siRNA treated vector
control. Likewise, if SPRR2A does not interfere with p300
acetylation of p53, p300 knock down should not alter the
Ac-K382-p53/total p53 ratio seen in the clone.
Results showed that p300 knock down in the SPRR2A
clone yielded a relative reduction in Ac-K382-p53 when
compared to the total p53 in the cell. This would occur if
SPRR2A reduces not only p300 directed acetylation of
p53 (which is further reduced by EP300 siRNA), but also
blocks the compensatory p300 independent pathway that
maintains Ac-K382-p53/total p53 levels in the vector con-
trol (Figure 1D). The same change in Ac-K382-p53 with
EP300 siRNA was obtained in two other stable SPRR2A
clones (data not shown). p300 acetylation of p53 requires
direct interaction between these two proteins and immu-
noprecipitation experiments showed that SPRR2A expres-
sion inhibits p300-p53 binding (Figure 1E).
We also considered that SPRR2A might bind directly to
p300 or p53 and interfere with subsequent acetylation,but immunoprecipitation experiments failed to show any
direct interaction (data not shown). Consequently, the
observed effect is likely upstream of these molecules.
Altogether our observations suggest that SPRR2A pre-
vents acetylation of K382-p53 in two ways: the first
involves p300: SPRR2A dissociates or blocks p300-p53
binding, which in turn prevents acetylation of K382-p53
by p300; the second is p300-independent: SPRR2A acts
through other p53 regulators to reduce the activation/
stabilization of p53. Since deacetylated p53 is less stable
and more readily degraded, SPRR2A stable clones have
less total p53 (Figure 1D), suggesting that SPRR2A ex-
pression yields less Ac-K382-p53 by enhancing ubiquiti-
nation and degradation.
SPRR2A down-regulates p53-DNA binding and target
gene transcription
Next, we determined whether SPRR2A expression influ-
ences p53 DNA binding activity using biotinylated
double-stranded oligonucleotide probes that mimic the
wild type or mutational sequences of known p53 binding
motifs [23]. Lysates from HuCCT-1 parent cells, trans-
fected with p53 vectors, show that p53 can bind with the
intact, wild type p53 response element (RE), but not the
mutated RE, indicating that p53 binding is sequence spe-
cific (Figure 2A and 2B). Over expression of p300 only
slightly increased p53 binding to this element (verified
by imageJ analysis), most likely because the binding
element is not in the context of the genome where DNA
conformation and upstream/downstream co-factor bind-
ing influences p53 binding. Co-existent SPRR2A expres-
sion in the protein lysate, however, decreased p53
binding to the element when compared to its corre-
sponding control: P53> p53/SPRR2A; p53/p300> p53/
p300/sprr2A. Furthermore, SPRR2A significantly reduced
this p53/RE binding in the absence of p300 over expres-
sion, supporting a role for SPRR2A in regulating p53
through non-p300 mechanisms (Figure 2B). DNA pull
down assays using wild type p53 RE motif did not show
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does not act as a transcription factor that competes with
p53 for binding to the response element (results not
shown). These results are in accordance with the above
hypotheses suggesting that the effect of SPRR2A on
K382-p53 acetylation is what modulates p53 DNA
binding.
These observations, however, still do not determine
whether SPRR2A and/or p300-mediated changes in p53
acetylation and DNA-binding affect p53 target gene tran-
scription. p53 regulates p21 gene expression by directly
binding to a p53-RE on the p21 promoter region[23], fol-
lowed by recruitment of p300/CBP and acetylation of
p53 [24]. We examined transcriptional activity using a
luciferase reporter vector containing the p21 promoter.
As shown in Figure 2C, over expression of p53 in
HuCCT-1 cells significantly increased the p21 promoter
activity, as expected. In addition, this effect was increasedFigure 2 SPRR2A dislocates p53 from its DNA binding element, reduc
double-stranded DNA probes that mimic the wild type and mutational p53
SPRR2A expression reduces p53 binding to the p53-RE when compared to
transfection with p53> p53/SPRR2A and transfection with p53/p300>p53
transfected with indicated vectors. For p53-RE reporter, we used wild type
reduced reporter activity when compared to the corresponding control tra
expression and acetylation of p300 and p53. WT, wild type; MT, mutation; *by co-transfection with a wild type p300 vector, but in
this reporter system it did not reach statistical signifi-
cance. SPRR2A expression decreased p21 promoter ac-
tivity significantly, with and without p300 over
expression, supporting previous data (Figure 1D) show-
ing that SPRR2A affects not only p300, but other p53
regulators as well. Although less effective, a luciferase
assay using p53-RE-luc and its mutational construct
demonstrated a similar reduction in activity after
SPRR2A expression (Figure 2C). These results show that
SPRR2A can affect transcription not only on the p21 pro-
moter, but on other promoters with a p53-RE as well.
To corroborate the above hypothesis suggested by the
luc-reporter assays, in vivo protein expression profiles
were examined following similar transfections in parent
HuCCT-1 (Figure 2D). Although the p21-luc reporter
did not yield a significant increase in p21 transcription
following combined p53/p300 transfection, Figure 2Ding target gene transcription. (A) Sequence for the biotinylated
response elements (RE). (B) DNA pull-down assay showing that
its corresponding control. That is, p53 binding strengths are as follows:
/p300/SPRR2A. (C) Luciferase assays of p21-RE and p53-RE from cells
(WT) and mutational (MT) RE vectors. Again, SPRR2A expression
nsfection. (D) Western blot analysis showing that SPRR2A reduced p21
, p< 0.05; ** <0.01, ***< 0.001.
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p21 expression in vivo. Furthermore, compared to wild
type p300, less Ac-K83-p53 and p21 protein is expressed
if ΔCH3 p300 is transfected. And finally, all p21 levels
are reduced in the presence of SPRR2A.
Insights into how SPRR2A interacts with p300 to in-
hibit p53 DNA binding are seen in Figure 2D. Wild
type-p300 is acetylated in HuCCT-1-parent cells, but
SPRR2A induction de-acetylated p300, indicating a pos-
sible mechanism of SPRR2A’s suppressive effect on p21
transcription (Figure 2D). p53 protein can bind to both
the CH1 and CH3 sites on p300, but the binding
sequences for each are different [25]. The CH3 site
interacts with many transcription factors, including p53
[26-28]. Similar to SPRR2A induction, transfection with
a CH3-deleted p300 vector reduced promoter activity
when compared to wild type p300 (Figure 2C). And in
accordance with the promoter assays, transfection with a
CH3-deleted p300 vector also diminished the level of
Ac-K382-p53 and p21 (Figure 2D). Since CH3-deleted
p300 protein was not acetylated, even in the absence of
SPRR2A in HuCCT-1 cells, the CH3 domain appears to
be crucial for p300 acetylation followed by p53 acetyl-
ation (Figure 2D). Moreover, expression of SPRR2A does
not exert an additional suppressive effect on promoter
activity in the CH3-deleted p300 expressing cells
(Figure 2C-D). This suggests that the effects of SPRR2A
(i.e., reduced Ac-K382-p53, Ac-p300 and p53-RE gene
transcription) require a functional CH3 domain on p300.
HDAC1 reduces p53 acetylation in SPRR2A cells
Previous data from our lab showed that SPRR2A func-
tions as a SH3 domain ligand using its xPxxP motifs
[15] and the p300 CH3 domain can bind to a xPxxP
motif on p53 [29]. Our initial hypothesis was that
SPRR2A contacts the CH3 domain of p300 and thereby
precludes contact of p300 with other co-factors, like
PCAF, thus preventing p300 acetylation. However,
immunoprecipitation studies failed to reveal direct
p300-SPRR2A binding. This led us to determine whether
other molecules might mediate the p300 and p53
deacetylation.
Histone deacetylases do not act independently, but are
recruited to complexes that regulate their deacetylase ac-
tivity [30]. Gene array data showed that among the his-
tone deacetylase superfamily, histone deacetylase 1
(HDAC1) was significantly upregulated in SPRR2A over
expressing cells (data not shown). HDAC1 was an at-
tractive candidate molecule for SPRR2A induced p53
deacetylation for the following reasons: 1) HDAC1
affects p53 acetylation through interactions with both
p300 [31] and other cofactors such as MDM2 and
mSin3a [7,32]; 2) HDAC1 acts as an antagonist of p53 in
the regulation of p21 transcription [33]; 3) HDAC1 isknown to complex with factors that mediate p53 ubiqui-
tination [7], targeting p53 for proteosomal degradation
and reducing total cellular p53 (Figure 1D) and; 4)
HDAC1 is required for TGF-β1 induced EMT in hepato-
cytes [34] and SPRR2A overexpression induces EMT in
cholangiocarcinoma cell lines[15].
To determine whether histone deacetylases mediate a re-
duction of Ac-K382-p53 during SPRR2A over-expression,
we used the deacetylase inhibitor trichostatin A (TSA),
which globally interferes with Class I and II deacetylase
activity. TSA is a powerful inhibitor of deacetylase ac-
tivity and treatment of SPRR2A cells with TSA resulted in
most all of the cellular p53 remaining in the acetylated
form (Figure 3A). This indicates that SPRR2A-induced
deacetylation of p53 can be reversed by class I/II deacety-
lase inhibition and that it is not controlled by a TSA-
resistant NAD dependent histone deacetylase such as
SIRT1 (class III) [35].
We next verified gene array data for HDAC1 by real
time PCR and western blotting (Figure 3B). Over ex-
pression of HDAC1 interfered with p53 activation by
binding to the CH3 domain of p300 and competitively
inhibiting p53-p300 interactions [31]. Since SPRR2A-
mediated p53 deacetylation and reduction of p21 ex-
pression required a functional p300 CH3 domain
(Figure 2), we next determined whether HDAC1 binds
to p300 in our cells. As shown in Figure 3C, endogen-
ous HDAC1 co-immunoprecipitates with p300. Because
SPRR2A cells over express HDAC1, there is more
p300-HDAC1 interaction, competitively inhibiting p53-
p300 binding.
We next inhibited HDAC1 expression using specific
siRNA to determine whether HDAC1 was the specific
deacetylase involved. Western blots show that reducing
HDAC1 in SPRR2A cells restores acetylated K382-p53
levels (Figure 3D). Additionally, knockdown of HDAC1
recovered some p300 acetylation in SPRR2A cells. This
agrees with a previous report that showed the associ-
ation of deacetylases with p300 regulates its own acetyl-
ation status [31]. Finally, we show that HDAC1 siRNA
not only increases Ac-K382-p53, but it increases p21
mRNA and protein expression (Figure 3D), implicating
this molecule in the SPRR2A induced deacetylation of
p53. Additionally, immunoprecipitation experiments
determined that there were no direct HDAC1/SPRR2A
protein interactions (data not shown).
Conclusion
Our algorithm for reduced p53 acetylation and target
gene transcription during SPRR2A over expression is
outlined in Figure 4. SPRR2A induction of HDAC1, in
combination with other cofactors, deacetylates Ac-K382-
p53 and targets the protein for ubiquitination and subse-
quent degradation (non-p300 pathway). HDAC1 also
Figure 3 HDAC1 modulates SPRR2A induced changes in p53 and p300 acetylation. (A) Exposure to the deacetylase inhibitor trichostatin A
(TSA) causes acetylation of most all of the p53 in SPRR2A cells, indicating a role for Class I and II deacetylases in the cellular affects of SPRR2A
expression. Concomitant with this TSA increase in p53 acetylation is an increase in p21 expression. (B) HDAC1 mRNA and protein expression are
increased in SPRR2A cells. (C) HDAC1 co-immunoprecipitates with p300 and there is more HDAC1/p300 binding in SPRR2A cells. (D) Knockdown
of HDAC1 with siRNA: increases p21 protein and mRNA expression; restores acetylated p53 in SPRR2A cells to levels seen in the untreated vector
control cells; and increases acetylated p300. Successful HDAC1 knock down was verified by both real-time PCR and western blotting. Real time
PCR analysis: comparative 2-ΔΔCT method (GAPDH internal control).
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reducing both p53 and p300 acetylation (p300 pathway).
Although SPRR2A does not bind directly to p300, it
might interfere with other cofactors involved with p300autoacetylation. All molecular mechanisms for reduced
p300 acetylation with SPRR2A over expression are not
known, but cannot be solely explained by increasing
HDAC1; further studies are needed.
Figure 4 A hypothetical model of how SPRR2A changes p53 acetylation and target gene transcription. Acetylated p53 has a greater
binding affinity to specific RE in the DNA, promoting target gene transcription. Upper diagram: Vector cells have lower HDAC1 deacetylase
activity, allowing acetylated p300 and other modulatory proteins to enhance K-382-p53 acetylation. Lower diagram: Enhanced HDAC1 expression
in SPRR2A cells directly deacetylates p53 and competitively inhibits acetylation through p300/p53 interactions. In addition, SPRR2A expression
reduces p300 acetylation, most likely through its effects on other proteins involved with p300 auto-acetylation.
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gene expression during cellular stress, some of which
might be disadvantageous during wound repair responses
in barrier epithelia. For example, p53 transcriptional activa-
tion can trigger cell-cycle arrest, apoptosis, senescence,
DNA repair, alter metabolism [36] and inhibit EMT [11].
SPRR2A, in contrast, functions as a suppressor of p53-
dependent transcriptional activity by reducing the levels of
acetylated p53. This deacetylation of p53 combined with
the inherent antioxidant qualities of SPRR [18] protects
SPRR2A expressing epithelial cells from damage and allows
them to transiently acquire the mesenchymal characteris-
tics needed for the restitution phase of wound repair.
Materials and methods
Cultured cells, and SPRR2A stable transfectants
The human intrahepatic cholangiocarcinoma cell line
HuCCT-1 was maintained as reported [37]. Methods to
obtain stable transfectants with a SPRR2A expressing
vector were previously published [15].
Plasmids
We used the C-terminal His-V5-tagged human SPRR2A
expression vector previously described [15]. A humanHalo-tagged p300 vector was purchased from Promega
(Madison, WI). Other plasmids, including luciferase re-
porter plasmids, were purchased from Addgene (Cam-
bridge, MA): luc-p21-promoter constructs; luc-p53-wt;
luc-p53-mut; Ha-p300; and Ha-p300 CH3 deletion.
Florescence imaging
The SPRR2A sequence was cloned into a DsRed mam-
malian expression vector (Addgene) and transfected into
HuCCT-1 cells grown on glass coverslips. 48 hours after
transfection, the coverslips were fixed for 1 hour in 1%
paraformaldehyde. Nuclear staining was done with
Hoechst dye. DsRed-SPRR2A and Hoechst florescence
was captured using an AxioImager M1 microscope (Carl
Zeiss, Gottingen, Germany) with a 40X objective lens,
NA= 0.95.
Biotinylated oligonucleotide precipitation assays
The probes for DNA pull-down assays are shown in
Figure 2A. The assays were carried out as described [38].
Briefly, twenty four hours after transfection, cells were
lysed with HKMG buffer (10 mM HEPES, pH 7.9;
100 mM KCl; 5 mM MgCl2; 10% glycerol; 1 mM DTT;
and 0.5% of NP-40) containing protease and phosphatase
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with ImmunoPure streptavidin-agarose beads (Pierce,
Rockford, IL). Pre-cleared lysates were then incubated
12 hours with 1 μg of the 5’-biotinylated double-
stranded oligonucleotides and 10 μg of competitor DNA
(poly(dI-dC) poly(dI-dC)) to eliminate non-specific pro-
tein/DNA interactions. Oligo-specific bound proteins
were collected with streptavidin-agarose beads, separated
by SDS-PAGE, and protein identification done by West-
ern blotting.
Transfections and luciferase reporter assay
Transfections with DNA plasmids or empty vector were
done with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) using the manufacturer’s recommended protocol
for adherent cells. p300 (s4696) and HDAC1(s73) knock
down transfections were done with target specific or
negative control (negative siRNA #1) SilencerW Select
siRNA (Ambion, Austin, TX) using RNAiMAX (Invitro-
gen). Luciferase assays were carried out with a Promega
assay kit system 24 hours post-transfection and mea-
sured on a luminometer.
Western blotting
Cell lysates were obtained using TNE buffer (50 mM Tris,
pH 8.0; 150 mM NaCl; 10% v/v NP40; 2 mM EDTA) con-
taining protease inhibitors 48 hours after treatments.
Cytosolic and nuclear proteins were separated using an
NE-PER extraction kit (Thermo Scientific, Rockford, IL).
Proteins were separated by SDS-PAGE and visualized
using enhanced chemiluminescence reagents (Pierce,
Rockford, IL). Antibodies (clone) used are the following:
p53 (DO1), GAPDH (0411), p300 (N15), and Ha (F-7)
HDAC1 (H-51) (Santa Cruz Biotechnology, Santa Cruz,
CA); V5 (Invitrogen); Halo (Promega); PCAF (C14G9),
acetylated lysine (9441), and Ac-K382-p53 (Lys 382) (Cell
signaling, Danvers, MA). Western blots were measured
using imageJ software ( http://rsbweb.nih.gov/ij/).
Immunoprecipitation
Cell lysates were obtained 48 hours post-treatment using
TNE buffer containing protease inhibitors. Immunopreci-
pitation was done with appropriate antibody and protein-
A DynabeadsW (Invitrogen) (for endogenous proteins) or
HaloLink (Promega) magnetic beads (for plasmid trans-
fected cells). Proteins were visualized by Western blotting.
Real-time PCR
Total RNA was extracted from cells 24 hours post-
transfection with HDAC1 siRNA using TrizolW (Invitrogen)
and following the manufacturer’s instructions. P21 and
HDAC1 expression was quantified by TaqManW real-time
PCR using specific primers (Applied Biosystems, Foster
City, CA). SPRR2A was done with SYBR Green usingpreviously described primers [39]. Gene expression was
normalized to GAPDH using the comparative 2-ΔΔCT
method, with expression levels in the untreated control set
to a value of 1.0.
Statistics
All statistical analyses were performed using SigmaStat
software. A P value of< 0.05 was considered statistically
significant, and all tests were two-tailed. All interval
values are expressed as mean ± SD. Group comparisons
were analyzed with Kruskal-Wallis ANOVA or one way
ANOVA.
Additional file
Additional file 1: Figure S1. SPRR2A deacetylates p53 in HepG2 cells,
which express only wild type p53. (A) Real time PCR shows HepG2 cells
do not normally express SPRR2A, but are successfully transfected with the
SPRR2A plasmid. The (+) control was a SPRR2A stably transfected clone
(cell line: SG231). (B) Western blot showing that transfection with
SPRR2A in HepG2 cells reduces acetylation of K-382-p53. Endogenous
p53 in HepG2 cells is wild type. (C) Real time PCR showing that SPRR2A
transfection also reduces p21 mRNA expression. Real time PCR analysis:
comparative 2-ΔΔCT method (GAPDH internal control); ** p<0.01;
***p< 0.001.
Abbreviations
CH, Cysteine and histidine-rich region; HDAC1, Histone deacetylase 1;
EMT, Epithelial-mesenchymal transition; SPRR2A, Small proline rich protein 2a,
RE, response element.
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